Peptide Therapy

Advanced Regenerative Medicine

TESAMORELIN

GHRH (1-44) Growth Hormone Releasing Hormone

·       Stimulates the pituitary gland to release endogenous growth hormone

·       Increased hepatic production of insulin-like growth factor-1 (IGF-1)

·       Reduces visceral abdominal fat and increased lipolysis

·       Improved protein synthesis

·       Supports tissue repair and collagen synthesis

EFFECTS

·       Reduction in visceral abdominal fat and waist circumference

·       Reduces liver fat

·       Improves cholesterol and triglycerides

·       Preservation or slight increase in lean body mass

·       May improve exercise recovery

·       May enhance tissue repair

·       May improve sleep quality

·       Increase age related GH decline

SIDE EFFECTS

  • Common: Injection site reaction, facial flushing, joint or joint aches, fluid retention, mild nausea

  • Uncommon: carpal tunnel syndrome, headache, tingling or numbness, vomiting, risk of increased IGF-1 levels promoting growth of existing malignancies

  • Contraindications: Active Malignancy

DOSING

  • Injection:  0.5mg-1mg daily 2 hours after last meal. 5-7nights/week

  • Oral: 0.5mg-1mg daily 2 hours after last meal. 5-7nights/week

STUDIES

· Faultz et al. 2007, Stanley et al. 2014/2019